Identifying the Perpetrator in Medulloblastoma: Dorian Gray versus Benjamin Button  by Lowry, Natalia Abramova & Temple, Sally
Khayrullina, T., Yen, J.H., Jing, H., and Ganea, D.
(2008). J. Immunol. 181, 721–735.
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu,
Y., Harris, T., Drake, C., Pardoll, D., and Yu, H.
(2009). Cancer Cell 15, this issue, 114–123.
Langowski, J.L., Kastelein, R.A., and Oft, M.
(2007). Trends Immunol. 28, 207–212.
Trinchieri, G., Pflanz, S., and Kastelein, R.A. (2003).
Immunity 19, 641–644.
Vicari, A.P., Chiodoni, C., Vaure, C., Ait-Yahia, S.,
Dercamp, C., Matsos, F., Reynard, O., Taverne,
C., Merle, P., Colombo, M.P., et al. (2002). J.
Exp. Med. 196, 541–549.
Wei, L., Laurence, A., and O’Shea, J.J. (2008).
Semin. Cell Dev. Biol. 19, 394–400.
Yang, J., Liao, X., Agarwal, M.K., Barnes, L.,
Auron, P.E., and Stark, G.R. (2007). Genes Dev.
21, 1396–1408.
Yu, H., Kortylewski, M., and Pardoll, D. (2007). Nat.
Rev. Immunol. 7, 41–51.
Zou, W. (2006). Nat. Rev. Immunol. 6, 295–307.
Cancer Cell
PreviewsIdentifying the Perpetrator in Medulloblastoma:
Dorian Gray versus Benjamin Button
Natalia Abramova Lowry1,2 and Sally Temple1,2,*
1New York Neural Stem Cell Institute, Rensselaer, NY 12144, USA
2Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, NY 12208, USA
*Correspondence: sallytemple@nynsci.org
DOI 10.1016/j.ccr.2009.01.010
Tumors contain a subpopulation of tumor-propagating cells (TPCs) that are critical for their growth. In this
issue, Read, Wechsler-Reya, and colleagues show that in an animal model of medulloblastoma, TPCs
express the surface marker CD15 and have properties distinct from neural stem cells.The idea that stem cells or their close
derivativesmight underlie tumor formation
has a long history but has come to the fore
with the advent of modern stem cell
biology. We now know that, for a variety
of tumors, there is an essential subpopula-
tion of cells that maintains the growth of
neoplastic tissue and can initiate new
tumors in vivo when transplanted into
a receptive host. These tumor-propa-
gating cells (TPCs) can resemble normal
tissue stem cells in their marker expres-
sion and their ability to self-renew and
produce differentiated progeny. For
a given tumor type, defining its constituent
TPCs is of paramount importance—first to
identify and target them to combat tumor
growth, and second to understand their
etiology and find ways to prevent tumor
formation. Do TPCs arise from normal
stem cells that go awry and proliferate
uncontrollably, disregarding regulatory
mechanisms that keep them in check, or
do they arise from later-stage progenitor
cells that revert to acquire stem-like
features? These two views of cancer
formation—reminiscent of the literary
characters of Dorian Gray, who didn’t
age, and Benjamin Button, who was born
old and grew young—are an active pointof debate. Recent studies indicate that
mutations in the stem cell compartment
more readily phenocopy colon cancer
(Barker et al., 2008). However the same
might not be true for cancers in other
tissues.
Medulloblastomas are the most com-
mon pediatric brain tumors. They occur in
the cerebellum, a brain region involved in
integrating sensory perception and move-
ment control. The cerebellum forms from
twomajor germinal regions, the ventricular
zone and the external granular layer
(Figure 1). The most abundant cell in the
brain, the cerebellar granule neuron, arises
from granule neuron precursors (GNPs) in
the external granular layer, largely during
the early postnatal period.
The remarkable expansion of GNPs is
governed principally by the growth factor
Sonic hedgehog (Shh) (Kenney et al.,
2003). The signaling cascade is initiated
by Shh binding to the cell surface receptor
Patched (Ptc). A key player in the cascade
is a G protein-coupled receptor-like mole-
cule called Smoothened (Smo). In the ab-
sence of Shh, Ptc inhibits the activity of
Smo. Shh binding to Ptc relieves its inhibi-
tion, andSmocansignal downstream.The
targets of Smo include Gli transcriptionCancer Cell 1factors, which then translocate to the
nucleus and initiate transcription.
Approximately 25% of medulloblas-
tomas result from inappropriate activation
of Shh signaling, and a subset of human
medulloblastomas harbor mutations of
the Ptc gene (Zurawel et al., 2000). A
useful model of medulloblastoma is the
Ptc+/ mutant mouse. Ptc haploinsuffi-
ciency increases proliferation of neural
stem cells (Galvin et al., 2007), and 15%–
20% of Ptc+/mice develop medulloblas-
tomas (Goodrich et al., 1997).
Read et al. (2009) examined medullo-
blastomas derived from Ptc+/ mice.
Using fluorescence-activated cell sorting
(FACS) with cell surface markers, they
separated subpopulations of live cells
and then stereotaxically injected these
into SCID/beige mouse cerebella to
examine whether they could form tumors.
Surprisingly, the investigators found that
medulloblastomas were not propagated
by cells expressing the neural stem cell
(NSC) marker CD133, leading them to
search for other candidate markers. A
prior study had described CD15, also
known as Lewis X (LeX) or stage-specific
embryonic antigen-1 (SSEA-1), as a
marker of forebrain NSCs and progenitor5, February 3, 2009 ª2009 Elsevier Inc. 83
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PreviewsFigure 1. Cerebellum Development
(A) Mature human brain showing the location of the cerebellum.
(B) Midgestation mouse brain indicating the early cerebellum immediately caudal to the colliculus.
(C) Dorsal view showing the developing cerebellum and the direction of progenitor cell migration from the
rhombic lip (RL) over the surface of the cerebellum to produce the external granular layer (EGL).
(D) Cross-section (dotted line indicated in [C]) showing the two major cerebellar germinal zones, the
ventricular zone (VZ) and the EGL. VZ progenitors are active in the embryonic period, and progeny migrate
radially toward the pia to form the early-born cerebellar cells, including the Purkinje neurons and Berg-
mann glia. Granule neuron precursors (GNPs) arise first in the RL and then proliferate and migrate over
the surface of the cerebellum, forming the EGL.
(E) Magnification of boxed area in (D) showing the EGL GNPs. These progenitor cells are stimulated by
Sonic hedgehog (Shh) to divide and generate immature granule neurons that migrate down the Bergman
glia to the internal granular layer (IGL).
(F) Scheme of cerebellar progenitor cell development in the EGL, identifying the basic cell compartments
that could transform into tumor-propagating cells (TPCs).cells that is highly expressed in the cere-
bellum anlage (Capela and Temple,
2006). Read et al. found that CD15 was
expressed by a subset of normal granule
precursor cells and medulloblastoma
cells. FACS-sorted CD15+ cells from
Ptc+/ medulloblastomas were able to
form tumors in vivo containing a charac-
teristic mixture of cells, although they
could not form neurospheres in culture.
CD15+ cells from Ptc+/ tumors exhibited
higher proliferation rates and elevated
levels of the Hh target genes Gli1 and
Cyclin D1 compared to CD15 cells,
consistent with Shh pathway activation.
Transcriptome comparison of the CD15+
and CD15 cells demonstrated that the
CD15+ cells expressed higher levels of
genes associated with progenitor cell
proliferation rather than differentiation
and migration, establishing a CD15-asso-
ciated gene ‘‘signature.’’84 Cancer Cell 15, February 3, 2009 ª2009 EThe authors then found that CD15 was
expressed in a subset of human medullo-
blastomas. Increased expression of the
CD15 gene signature was associated
with shorter survival time of medulloblas-
toma patients. Future studies aimed at
understanding the functional significance
of CD15 and associated genes should be
enlightening in understanding its prog-
nostic value. This carbohydrate moiety
can bind Wnt-1 and fibroblast growth
factors, so it could enhance progenitor
cell activity by supplying bioactive
molecules.
Three basic cell compartments could
give rise to TPCs after undergoing
neoplastic transformation: NSCs, transit-
amplifying progenitor (TAP) cells, and
differentiated cells. Given the lack of
CD133 association, neurosphere forma-
tion, and multilineage potential and the
expression of CD15, the authors suggestlsevier Inc.that these medulloblastoma TPCs are
related not to normal cerebellar stem cells
(Lee et al., 2005) but to later progenitor
cells that have acquired tumor-generating
properties. There is a growing literature
indicating that some brain cancer TPCs
lack CD133 (e.g., Wang et al., 2008),
lending support to the TAP origin hypoth-
esis—with a couple of caveats. First, lack
of CD133 might reflect loss of the marker
rather than origination from a negative
cell. Indeed, CD133 expression has been
linked to hypoxic stress, so expression
levels among tumor cells might reflect
microenvironment more than lineage orig-
ination (Griguer et al., 2008). And second,
CD133 expression might not encompass
all stem cells—especially in a tissue such
as the cerebellum, where development is
protracted and the germinal tissue is
complex (Figure 1).
The lack of neurosphere generation
from these Ptc+/ medulloblastoma TPCs
is particularly surprising, as a variety of
NSCs and TAP cells can produce neuro-
spheres. It is conceivable that some
stem/progenitors require a niche to prolif-
erate and are unable to form neuro-
spheres. Whatever their derivation, it is
intriguing that these TPCs appear to have
specific growth requirements that depend
on cell-cell interactions: thismight present
an Achilles’ heel that can be targeted.
Thus, while Ptc+/ medulloblastoma
TPCs lack some NSC features and, we
extrapolate, might therefore have a TAP
origin, reliance on a handful of markers
and functional assays leaves room for
different interpretations. A more direct
test of origination might be to take the
promoter-based approach of Barker et al.
(2008) and compare the effect of reduced
levels of Patched signaling in targeted
CD133+ versus TAP cells in vivo.
We do need to keep in mind that tumor
cells might defy the logic of normal
lineage relationships: the fact that they
can coexpress neuronal and glial differen-
tiation markers (Hemmati et al., 2003)—
taboo in normal cells—indicates that
they are as abnormal as the fictitious
Dorian Gray or Benjamin Button. TPCs in
individual tumors may have different
cellular origins, and they may be dynami-
cally evolving with unstable marker
expression. Although they present
a daunting, moving, and complex target,
full characterization of TPCs using the
powerful tools of cell separation and
Cancer Cell
Previewscomprehensive molecular characteriza-
tion, as beautifully illustrated in the Read
et al. study, along with similar definition
of normal progenitor lineages should
allow TPC categorization and ultimately
a fuller understanding of the disease for
design of individualized treatments.
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